2025-08-26 - Analysis Report
Okay, here's a report summarizing the information provided about Johnson & Johnson (JNJ), incorporating numerical data, analysis, and considering the context of S&P 500 performance.

## Johnson & Johnson (JNJ) Stock Analysis

**Company Overview:** Johnson & Johnson (JNJ) is a global healthcare company engaged in the research and development, manufacture, and sale of a broad range of products in the healthcare field.

### 1. Performance vs. S&P 500 (VOO)

**Key Numbers:**

*   **JNJ Cumulative Return:** 31.22%
*   **VOO Cumulative Return:** 38.23%
*   **Absolute Difference:** -7.0%
*   **Relative Difference (Percentile):** 17.4% (Indicates the current difference is near the lower end of its historical range).
* **Alpha,Beta Analysis**

| Year       | CAGR   | MDD    | Alpha   | Beta   | Cap(B)   |
|------------|--------|--------|---------|--------|----------|
| 2015-2017  | 28.0%  | 56.1%  | 28.0%   | 1.0    | 336.5    |
| 2016-2018  | 8.0%   | 56.6%  | 8.0%    | 1.0    | 310.8    |
| 2017-2019  | 18.0%  | 56.6%  | 18.0%   | 1.0    | 351.3    |
| 2018-2020  | 12.0%  | 59.2%  | 12.0%   | 1.0    | 379.0    |
| 2019-2021  | 32.0%  | 59.6%  | 31.0%   | 0.0    | 412.0    |
| 2020-2022  | 7.0%   | 61.4%  | 18.0%   | -0.0   | 425.4    |
| 2021-2023  | -15.0% | 61.4%  | -25.0%  | -0.0   | 377.5    |
| 2022-2024  | -35.0% | 61.4%  | -65.0%  | -0.0   | 348.3    |
| 2023-2025  | 4.0%   | 70.1%  | -40.0%  | -0.0   | 429.7    |

**Analysis:**

*   JNJ has underperformed the S&P 500 (VOO) in terms of cumulative return.
*   The relative difference suggests JNJ is currently lagging the S&P 500 more than it historically has.
*   Alpha values are varied with negative values occuring for longer period.
*   Beta values close to 0 indicate that price is theoretically independant of the market.
*   MDD is around 60% through 2018 to 2024, which suggests high risk.

### 2. Recent Stock Price Movement

**Key Numbers:**

*   **Current Price:** \$178.41
*   **Previous Close:** \$179.29
*   **Change:** -0.49
*   **5-day Moving Average:** 178.65
*   **20-day Moving Average:** 173.33
*   **60-day Moving Average:** 162.56

**Analysis:**

*   The stock price decreased slightly from the previous day.
*   The price is trading above the 20-day and 60-day moving averages, suggesting a potential upward trend in the short to medium term.
*   The price is slightly below the 5-day moving average, indicating a possible short-term pullback or consolidation.

### 3. Market Risk Indicators and Expected Return

**Key Numbers:**

*   **Market Risk Indicator (MRI):** 0.32 (Medium Risk)
*   **RSI:** 80.46 (Overbought)
*   **PPO:** 0.0252
*   **Hybrid Signal:** cash_0%_Buy 80% of cash (1 shares - Caution - MRI:0.34)
*   **20-day Relative Divergence Change:** +1.8 (Short-term increase in relative divergence)
*   **Expected Return:** 100.1% (Long-term, relative to S&P 500)

**Analysis:**

*   The MRI suggests a medium level of market risk.
*   The RSI is in overbought territory, indicating the stock may be due for a correction or consolidation.
*   The positive change in relative divergence over 20 days suggests short-term upward momentum compared to the S&P 500.
*   The significant expected return suggests potential for substantial outperformance over the S&P 500 in the long term if investing from this point.
*   Last-market change suggests there is a small issue in the price change.

### 4. Recent News & Significant Events

*   **Volatility:** Stock has shown notable volatility.
*   **Analyst Discussions:** Recent performance and outlook are being discussed in the context of industry trends and global economic factors.
*   **Business Developments/Regulatory Changes:** JNJ has recently made headlines due to major business developments, regulatory changes, or market events.
*   **Expert Advice:** Market experts highlight both risks and opportunities, advising investors to monitor recent news and company announcements.

**Analysis:** Recent news points to volatility and significant events impacting JNJ.  Investors should carefully monitor news releases and analyst reports to assess the impact of these factors on the stock.

### 5. Recent Earnings Analysis

| 날짜       | EPS  | 매출        |
|------------|------|-------------|
| 2025-07-24 | 2.3  | 23.74 B$    |
| 2025-04-23 | 4.57 | 21.89 B$    |
| 2024-10-23 | 1.12 | 22.47 B$    |
| 2024-07-25 | 1.95 | 22.45 B$    |
| 2025-07-24 | 1.95 | 22.45 B$    |

**Analysis:**

*   Revenue appears relatively stable over the last few quarters, with some fluctuation.
*   EPS shows more significant variation, potentially indicating changes in profitability or one-time events.
*   It appears that 2025-07-24 data is repeated.

### 6. Financial Information

**Revenue and Profitability:**

| Quarter      | Revenue    | Profit Margin |
|--------------|------------|---------------|
| 2025-06-30   | \$23.74B   | 67.87%        |
| 2025-03-31   | \$21.89B   | 66.40%        |
| 2024-12-31   | \$22.52B   | 68.35%        |
| 2024-09-30   | \$22.47B   | 69.01%        |
| 2024-06-30   | \$22.45B   | 69.40%        |

**Capital and Profitability:**

| Quarter      | Equity     | ROE     |
|--------------|------------|---------|
| 2025-06-30   | \$78.47B   | 7.06%   |
| 2025-03-31   | \$78.11B   | 14.08%  |
| 2024-12-31   | \$71.49B   | 4.80%   |
| 2024-09-30   | \$70.16B   | 3.84%   |
| 2024-06-30   | \$71.54B   | 6.55%   |

**Analysis:**

*   **Revenue:** Revenue is consistent, hovering around $22-24 billion per quarter.
*   **Profit Margin:** Profit margins are very strong and relatively stable, consistently above 66%.
*   **Equity:** Equity has generally been increasing.
*   **ROE:** ROE fluctuates, but generally indicates profitability. The high ROE in 2025-03-31 stands out and may warrant further investigation to understand the driver.

### 7. Overall Summary and Conclusion

Johnson & Johnson (JNJ) is a large, established healthcare company. While it has recently underperformed the S&P 500, its financial health appears robust, with consistent revenue and strong profit margins. Recent news suggests increased volatility and potential impactful events. The RSI indicates the stock might be overbought in the short term. However, the longer-term expected return is significant.

**Investment Recommendation:**

*   **Caution:** Given the overbought RSI and recent underperformance, investors should exercise caution in the short term.
*   **Potential Long-Term Opportunity:** The high expected return and solid financial performance suggest JNJ could be a valuable addition to a long-term investment portfolio.
*   **Monitor News & Events:** Investors should closely monitor news and company announcements to assess the impact of recent business developments, regulatory changes, and market events. The hybrid signal also indicates caution.
*   **Look for a Pullback:** A pullback from the current overbought condition could present a more attractive entry point for long-term investors.
